In contrast to the overexpression of GFAP seen in animals treated with ADSCs (Clairembault et al., 2014), it was shown that ADSC-EVs markedly decreased the gene expression of GFAP, restored astrocytic injury, and improved motor performance in their Parkinson’s disease model (Meligy et al., 2019). This evidence concerns the gene GFAP and Parkinson disease.